- Phase (Ph) I/II study of sitravatinib (Sitra) alone or with tislelizumab (TIS) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/ GEJC)Li, J.; Bai, Y.; Chen, Z.; Ying, J.; Guo, Y.; Fang, W.; Zhang, F.; Xiong, J.; Zhang, T.; Meng, Z.; Zhang, J.; Yu, F.; Zhang, J.; Zhang, Z.; Qin, S.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)Chen, Zhendong; Bai, Yuxian; Zhang, Tao; Ying, Jieer; Lin, Xiaoyan; Yang, Liu; Wang, Jun; Zhang, Juan; Yu, Fan; Fei, Cong; Huang, Ruiqi; Li, JinASCO Gastrointestinal Cancers Symposium, San Francisco, CA, 2022-01-20 To 2022-01-22.被引 1
- Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 Chinese subpopulation analysisQin, S.; Guo, Y.; Meng, Z.; Wu, J.; Gu, K.; Zhang, T.; Lin, X.; Lin, H.; Ying, J-E.; Zhou, F.; Hsing-Tao, K.; Chao, Y.; Li, S.; Chen, Y.; Boisserie, F.; Abdrashitov, R.; Bai, Y.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.被引 1
会议论文
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC)
3被引8阅读
